Tag: psychiatric disorders
University of Sydney spinout bags $273m for psychiatric drug dev’t
Kinoxis Therapeutics, a University of Sydney spinoff, announced a partnership with German pharmaceutical company Boehringer Ingelheim to develop precision therapies that target oxytocin aimed at enhancing the quality of life for people with psychiatric disorders.
Featured Article
Smarter energy decisions: GridBeyond unveils AI-powered Bid Optimiser in Australia
As Australia’s energy transition accelerates, businesses participating in the National Electricity Market (NEM) are facing growing challenges in managing their energy assets efficiently.
